Greene Barry E — SEC insider filings
SEC reporting owner CIK 1291963. 25 insider filings on record with FilingPulse; latest filed 2026-10-19.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2020-08-11 to 2026-10-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 46,940 shares, $2,015,704 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 44,530 shares, $5,487,594 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 39.
- Largest priced transaction: sale of 27,109 shares @ $123.39 ($3,344,980) in ALNYLAM PHARMACEUTICALS, INC., filed 2020-09-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | President | 2 | — | 3 legs · 44,530 sh · $5,487,594 | 15 |
| Sage Therapeutics, Inc. (SAGE) | President and CEO, Director | 12 | 3 legs · 46,940 sh · $2,015,704 | — | 13 |
| Karyopharm Therapeutics Inc. (KPTI) | Director | 7 | — | — | 8 |
| ACORDA THERAPEUTICS INC (ACOR) | Director | 1 | — | — | 1 |
| CITY THERAPEUTICS, INC. (CTY) | Director | 2 | — | — | 1 |
| Dyne Therapeutics, Inc. (DYN) | Director | 1 | — | — | 1 |
Insider filings — Greene Barry E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-19 | 4 | CITY THERAPEUTICS, INC. (CTY) | Grant/award (A): 22,649 (derivative) @ $0 | EDGAR |
| 2026-10-15 | 3 | CITY THERAPEUTICS, INC. (CTY) | Holdings only — no transactions reported | EDGAR |
| 2026-06-23 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 57,463 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2025-07-31 | 4 | Sage Therapeutics, Inc. (SAGE) | Code (U): 46,940 · Disposition to issuer (D): 53,229 · Disposition to issuer (D): 174,000 (derivative) | EDGAR |
| 2025-05-29 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 4,600 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 19,964 @ $0 · Tax withholding (F): 4,862 @ $6.91 | EDGAR |
| 2024-08-07 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 50,400 @ $0 · Tax withholding (F): 12,273 @ $8.96 | EDGAR |
| 2024-05-30 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 69,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 168,000 (derivative) @ $0 | EDGAR |
| 2023-08-08 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2022-11-15 | 4 | Sage Therapeutics, Inc. (SAGE) | Purchase (P): 14,500 @ $34.48 | EDGAR |
| 2022-08-15 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Option exercise (M): 7,576 @ $1.49 · Option exercise (M): 7,576 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 23,900 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 69,920 (derivative) @ $0 | EDGAR |
| 2021-08-09 | 4 | Sage Therapeutics, Inc. (SAGE) | Purchase (P): 23,640 @ $43.15 | EDGAR |
| 2021-06-17 | 4 | Sage Therapeutics, Inc. (SAGE) | Purchase (P): 8,800 @ $56.32 | EDGAR |
| 2021-06-04 | 4 | ACORDA THERAPEUTICS INC (ACOR) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-05-21 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 23,900 (derivative) @ $0 | EDGAR |
| 2021-01-06 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 390,000 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | Sage Therapeutics, Inc. (SAGE) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Gift (G): 3,176 @ $0 · Option exercise (M): 44,530 @ $9.14 · Sale (S): 14,075 @ $122.66 · Sale (S): 27,109 @ $123.39 · Sale (S): 3,346 @ $124.38 · Gift (G): 155 @ $0 · +4 more | EDGAR |
| 2020-08-11 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,587 @ $63 · Option exercise (M): 1,036 @ $96.45 · Option exercise (M): 1,124 @ $88.95 · Option exercise (M): 1,184 @ $42.22 · Option exercise (M): 1,184 (derivative) @ $0 · Option exercise (M): 1,587 (derivative) @ $0 · +2 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1291963 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs